Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 20/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13325095 | 0.89 | CRHR1 (0.85) | CRHR1 | |
| Hydrochloric Acid SCHEMBL3287217 | 0.88 | CRHR1 (0.85) | CRHR1 | |
| SCHEMBL13325117 | 0.88 | CRHR1 (1.00) | CRHR1 | |
| SCHEMBL13325069 | 0.87 | CRHR1 (0.85) | CRHR1 | |
| SCHEMBL13325066 | 0.86 | CRHR1 (0.84) | CRHR1 | |
| SCHEMBL13324997 | 0.85 | CRHR1 (1.00) | CRHR1 | |
| SCHEMBL13325126 | 0.85 | CRHR1 (1.00) | CRHR1 | |
| SCHEMBL3284292 | 0.85 | CRHR1 (1.00) | CRHR1 | |
| SCHEMBL13325122 | 0.84 | CRHR1 (1.00) | CRHR1 | |
| SCHEMBL2055890 | 0.84 | CRHR1 (0.70) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7714009-B2 | Nitrogen-containing fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-11 | — | — | US | disclosed |
| US-7714009-B2 | Nitrogen-containing fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-11 | — | — | US | disclosed |
| US-20070135452-A1 | Nitrogen-containing fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-06-14 | — | — | US | disclosed |
| US-20070135452-A1 | Nitrogen-containing fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135452-A1 | Nitrogen-containing fused heterocyclic compounds | NPY4R, NR4A3, NR3C2 | CRHR1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.